Withdrawals due to adverse events · adults with SAnD
It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD
1 finding from 1 review
Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
2 findings from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: dry mouth compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: spasmophilia · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: spasmophilia compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: euphoric behaviour · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: euphoric behaviour compared with placebo (very low certainty).
1 finding from 1 review
Change in QoL - depression (surrogate marker) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in QoL - depression (surrogate marker) compared with placebo (very low certainty).
1 finding from 1 review
Change in taste · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam) changes change in taste compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) · bipolar disorder
Lamotrigine showed no clear difference in recurrence of any episodes at one year for clinical worsening with… compared with lithium (moderate certainty).
1 finding from 1 review
Recurrence of any episodes at one year for clinical worsening with additional psychotropics (mood stabilizers, antidepressants, antipsychotics or benzodiazepines) · bipolar disorder
Lamotrigine probably leads to lower recurrence of any episodes at one year for clinical worsening with… compared with placebo (moderate certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
Antidepressants showed no clear difference in failure to respond compared with benzodiazepines (low certainty).
1 finding from 1 review
panic symptoms · adults with panic disorder
2 findings from 1 review
Withdrawals due to adverse events · adults with panic disorder
TCAs may leads to higher number of dropouts due to adverse effects compared with benzodiazepines (low certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · adults with panic disorder
It is very uncertain whether SSRIs changes failure to respond compared with benzodiazepines (very low certainty).
1 finding from 1 review